Probatebeta
Target

AXL

Tyrosine-protein kinase receptor UFO

As of the edition of 20 October 2026, AXL (tyrosine-protein kinase receptor UFO, UniProt P30530) has 15 drugs tested at it and 18 companies on the list, 9 on route A and 1 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P30530
How well studied
Chemical tools exist; no approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
4
Disease areas
Cancer; Blood and lymph; Lungs and airways; Digestive system; Hormones; Immune system; Pregnancy and women's health; Skin and connective tissue
Registered trials of its drugs
115

Drugs at this target

StatusCount
Marketed1
Active4
Stopped7
Status not established3
Total15
DrugStatusFurthest phaseUS protection
GilteritinibMarketedPhase 3Ends 2032
BemcentinibStoppedPhase 3none listed
NingetinibStoppedPhase 2none listed
DubermatinibStoppedPhase 3none listed
TamnorzatinibActivePhase 2none listed
Q702ActivePhase 2none listed
SLC-391StoppedPhase 2none listed
BPI-9016Status not establishedPhase 1none listed
DS-1205cStoppedPhase 1none listed
INCB081776StoppedPhase 1none listed
Mecbotamab vedotinStatus not establishedPhase 2none listed
XZB-0004ActivePhase 1none listed

12 of 15 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A9
Route B1
Engaged5
Undetermined3
Total on the list18
Three companies on route A or B, with the route only
CompanyRoute
AstellasRoute B
IncyteRoute A
Jiangsu Alphamab BiopharmaceuticalsRoute A

The other 15 companies at AXL

In the product

18 companies in all; 15 are not named here, and no score is.

See the 18 companies at AXL, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at AXL

Other targets in cancer